These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 24998941)

  • 41. Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.
    Lanier OL; Manfre MG; Bailey C; Liu Z; Sparks Z; Kulkarni S; Chauhan A
    AAPS PharmSciTech; 2021 Mar; 22(3):107. PubMed ID: 33719019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trans-scleral delivery of macromolecules.
    Pescina S; Santi P; Ferrari G; Nicoli S
    Ther Deliv; 2011 Oct; 2(10):1331-49. PubMed ID: 22826887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Turning the screw even further to increase microparticle retention and ocular bioavailability of associated drugs: The bioadhesion goal.
    Rodríguez Villanueva J; Rodríguez Villanueva L
    Int J Pharm; 2017 Oct; 531(1):167-178. PubMed ID: 28822703
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hydrogel eye drops as a non-invasive drug carrier for topical enhanced Adalimumab permeation and highly efficient uveitis treatment.
    Chen Z; Yang M; Wang Q; Bai J; McAlinden C; Skiadaresi E; Zhang J; Pan L; Mei C; Zeng Z; Yu J; Feng Y; Jiang Z; Xu W; Xu H; Ye X; He H; Wang Q; Deng J; Huang J
    Carbohydr Polym; 2021 Feb; 253():117216. PubMed ID: 33278980
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implantable sustained-release drug delivery systems: a revolution for ocular therapeutics.
    Cong YY; Fan B; Zhang ZY; Li GY
    Int Ophthalmol; 2023 Jul; 43(7):2575-2588. PubMed ID: 36715956
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A New Direction in Ophthalmic Development: Nanoparticle Drug Delivery Systems.
    Andonova VY
    Curr Pharm Des; 2016; 22(41):6313-6329. PubMed ID: 27526789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ophthalmic drug delivery systems--recent advances.
    Bourlais CL; Acar L; Zia H; Sado PA; Needham T; Leverge R
    Prog Retin Eye Res; 1998 Jan; 17(1):33-58. PubMed ID: 9537794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery.
    Kaur IP; Smitha R
    Drug Dev Ind Pharm; 2002 Apr; 28(4):353-69. PubMed ID: 12056529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emphasis on Nanostructured Lipid Carriers in the Ocular Delivery of Antibiotics.
    Singh CP; Rai PK; Kumar M; Tiwari V; Tiwari A; Sharma A; Sharma K
    Pharm Nanotechnol; 2024; 12(2):126-142. PubMed ID: 37519002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improvement in Ocular Bioavailability and Prolonged Delivery of Tobramycin Sulfate Following Topical Ophthalmic Administration of Drug-Loaded Mucoadhesive Microparticles Incorporated in Thermosensitive In Situ Gel.
    Khan S; Warade S; Singhavi DJ
    J Ocul Pharmacol Ther; 2018 Apr; 34(3):287-297. PubMed ID: 29211593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations.
    Shen J; Lu GW; Hughes P
    Pharm Res; 2018 Sep; 35(11):217. PubMed ID: 30255364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Delivery of antiglaucoma drugs: ocular vs systemic absorption.
    Urtti A
    J Ocul Pharmacol; 1994; 10(1):349-57. PubMed ID: 8207339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Silk Fibroin Formed Bioadhesive Ophthalmic Gel for Dry Eye Syndrome Treatment.
    Hao T; Tang L; Xu Q; Wang W; Li Z; Shen Y; Xu B; Luo H; Li Q; Wang J; Zhang J
    AAPS PharmSciTech; 2024 Apr; 25(5):92. PubMed ID: 38684590
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A biomimetic peptide-drug supramolecular hydrogel as eyedrops enables controlled release of ophthalmic drugs.
    Pan M; Ren Z; Ma X; Chen L; Lv G; Liu X; Li S; Li X; Wang J
    Acta Biomater; 2023 Sep; 167():195-204. PubMed ID: 37392932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of ocular drug delivery systems using molecularly imprinted soft contact lenses.
    Tashakori-Sabzevar F; Mohajeri SA
    Drug Dev Ind Pharm; 2015 May; 41(5):703-13. PubMed ID: 25113431
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sustained release ocular drug delivery systems for glaucoma therapy.
    Al-Qaysi ZK; Beadham IG; Schwikkard SL; Bear JC; Al-Kinani AA; Alany RG
    Expert Opin Drug Deliv; 2023; 20(7):905-919. PubMed ID: 37249548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept.
    Patel N; Thakkar V; Metalia V; Baldaniya L; Gandhi T; Gohel M
    Drug Dev Ind Pharm; 2016 Sep; 42(9):1406-23. PubMed ID: 26716613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug delivery to the posterior segment of the eye.
    Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
    Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Barriers to glaucoma drug delivery.
    Ghate D; Edelhauser HF
    J Glaucoma; 2008 Mar; 17(2):147-56. PubMed ID: 18344762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ophthalmic drug dosage forms: characterisation and research methods.
    Baranowski P; Karolewicz B; Gajda M; Pluta J
    ScientificWorldJournal; 2014; 2014():861904. PubMed ID: 24772038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.